Vupanorsen

DRUG3 trials

Sponsors

Pfizer

Conditions

DyslipidemiasHealthyHyperlipidemiasHyperlipoproteinemias

Phase 1

Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides

CompletedNCT04459767

Start: 2020-08-06End: 2020-12-15Updated: 2020-12-22

A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Single Dose Vupanorsen In Healthy Chinese Adults

CompletedNCT04916795

Start: 2021-06-17End: 2021-10-19Updated: 2024-03-12

Phase 2

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

CompletedNCT04516291

PfizerDyslipidemias, Hyperlipidemias, Hyperlipoproteinemias

Start: 2020-09-28End: 2021-12-06Updated: 2022-10-04

Related Papers

A Randomized, Open-Label, Phase I, Single-Dose Study of Antisense Oligonucleotide, Vupanorsen, in Chinese Adults with Elevated Triglycerides.

2024-06-011 citations

A multi‐purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo‐controlled, single‐ascending dose study in adults

Clinical and Translational Science2023-03-3110 citations

Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

Circulation2022-04-03179 citations

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

European Heart Journal2021-11-26185 citations